Cardiovascular Disease: Should Statin Therapy Be Expanded in Patients with CKD?

Overview

Journal Nat Rev Nephrol

Specialty Nephrology

Date 2012 Jul 4

PMID 22751508

Citations 1

Authors

Kristen L Jablonski

Michel Chonchol

Affiliations

Soon will be listed here.

Citing Articles

Raising awareness of acute kidney injury: a global perspective of a silent killer.

Lewington A, Cerda J, Mehta R Kidney Int. 2013; 84(3):457-67.

PMID: 23636171 PMC: 3758780. DOI: 10.1038/ki.2013.153.

References

. Protocol for a prospective collaborative overview of all current and planned randomized trials of cholesterol treatment regimens. Cholesterol Treatment Trialists' (CTT) Collaboration. Am J Cardiol. 1995; 75(16):1130-4. DOI: 10.1016/s0002-9149(99)80744-9. View

Wanner C, Krane V, Marz W, Olschewski M, Mann J, Ruf G . Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005; 353(3):238-48. DOI: 10.1056/NEJMoa043545. View

Fellstrom B, Jardine A, Schmieder R, Holdaas H, Bannister K, Beutler J . Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009; 360(14):1395-407. DOI: 10.1056/NEJMoa0810177. View

Ridker P, Danielson E, Fonseca F, Genest J, Gotto Jr A, Kastelein J . Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008; 359(21):2195-207. DOI: 10.1056/NEJMoa0807646. View

Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, Barnes E . The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012; 380(9841):581-90. PMC: 3437972. DOI: 10.1016/S0140-6736(12)60367-5. View

Taylor F, Ward K, Moore T, Burke M, Davey Smith G, Casas J . Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2011; (1):CD004816. PMC: 4164175. DOI: 10.1002/14651858.CD004816.pub4. View

Navaneethan S, Hegbrant J, Strippoli G . Role of statins in preventing adverse cardiovascular outcomes in patients with chronic kidney disease. Curr Opin Nephrol Hypertens. 2011; 20(2):146-52. DOI: 10.1097/MNH.0b013e3283435f0e. View

Ray K, Seshasai S, Erqou S, Sever P, Jukema J, Ford I . Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65,229 participants. Arch Intern Med. 2010; 170(12):1024-31. DOI: 10.1001/archinternmed.2010.182. View

Tonelli M, Lloyd A, Clement F, Conly J, Husereau D, Hemmelgarn B . Efficacy of statins for primary prevention in people at low cardiovascular risk: a meta-analysis. CMAJ. 2011; 183(16):E1189-202. PMC: 3216447. DOI: 10.1503/cmaj.101280. View

10.

Baigent C, Landray M, Reith C, Emberson J, Wheeler D, Tomson C . The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011; 377(9784):2181-92. PMC: 3145073. DOI: 10.1016/S0140-6736(11)60739-3. View